Thanks, Jackie.
As of our study pandemic. clinical will impact through I with our on update, best estimate the the I go see our of you share based today from coronavirus status the we
supporting than on COVID-XX. been sites, and dozen they our patients trials, as more with of deal in a studies As strain focus a the on the partner clinical and our our enrolled all investigators, collaborator has
response As and the our ability of to assess patient meets Jackie best patient basis. on operations to disruption clinical team daily mitigate mentioned, our by situation the evolving
quarter deficiency, deficiency. first In Mitapivat, for in most several achieved PKR evaluated start our this thalassemia activator, program I'll the our we and PK with currently disease. in lead sickle of kinase advanced milestones year, being important pyruvate cell
We therapy potential provide the have for first the this to modifying disease. disease
number years on by of including March, treatment orphan exclusivity. application the positive benefits, opinion deficiency. for CHMP In market XX was drug of a issued EMA the orphan provides for designation of drug with Mitapivat PK with designation adults its a us
PK completed patients enrollment regularly Mitapivat deficiency Phase are X not transfused. in ACTIVATE study the in who we addition, In
PK enrolled patients. we patients the study are transfused deficiency in enrolled XX total ACTIVATE-T in In patients. we Who regularly XX
everything study courier medical regardless includes local both drug. center. shipments study on to capture and ability focus we For access laboratories home patient's is to visits, get their use and to do can approaches, of of to ensure our clinical This of to to studies have now drug patients data the telemedicine
knowledge, date. To these no study of on our a as missed drug these result have patients efforts, studies to
year, studies to our both affected end an we access to later with pandemic. challenges this As period sites data by comes most areas anticipate the the of those ability to do particularly [ph], core
Given anticipate end studies sometime XXXX between and topline both XXXX. from this, data the the we now of of middle
of of has Based and PK will patient once deficiency occurred. XXXX. better on we in our to potential our narrow allow to once database further ability these timelines current assumptions, for participating lock achieve is Mitapivat monitoring approval expected a sites will how in occur understanding visit when have access affect to last visits We now the hope
study mitapivat thalassemia, completed enrollment of in in patients Phase of year the initial to XX this our we study the XX. enrollment Moving above target earlier X with
established equal in thalassemia in data this X patients. to proof-of-concept on trial, we g/dL you As of from evaluable may greater December that X treatment demonstrating than response interim hemoglobin in based X induced or with recall, mitapivat of
Data patients format have from included in presentation thalassemia, been Association June and for the this XX efficacy Hematology using which evaluable European Congress beta year. is accepted those at a virtual with held alpha being
at the in Institutes the sickle Chan the cell for EHA. As presentation of from data we've submitted disclosed study mitapivat proof-of-concept Health National of of disease previously,
for NIH of to the December. the Meeting data the presentation Although the decided to not has virtual accepted, in submit Annual data new at the and format were meeting, present it ASH due the instead
are on XXXX. for cell is this mitapivat. safety, disease in doses still of The on of and pharmacodynamics of tolerability, a We proof-of-concept to decision goal make mitapivat study to evaluate sickle track oral pharmacokinetics [indiscernible] escalating
for mg up b.i.d. is and the XX daily mitapivat to mg Chan patients mg, Dr. this patients those Dr. though XXX protocol, twice pandemic. paused original COVID-XX doses enroll the to weeks. in of XX XX study X in study, the mg for addition amended light two to to up plans In the in enrollment currently evaluated Chan of recently
PKR ascending clearance the Phase a study approximately The activator followed Mitapivat have AG-XXX and FDA In study ascending AG-XXX we volunteer cohort for initiate a cohort. XX developed healthy multiple to evaluate AG-XXX. healthy next single a mid Phase we March Beyond X in X dose application in dose in volunteers received from XXXX. we by will IND the expect geneneral
potentially safety, and AG-XXX, The tolerability, goal a dosing. to evaluate is pharmacokinetics therapeutic of pharmacodynamics
in the to the addition, and with supports In tolerability have continued option profile dose we sickle if safety dosing. adults disease enroll cell cohorts multi-ascending further included
move to now I'll malignant our hematology programs.
We are To time, and TIBSOVO. relapsed for inhibitor EU our the anticipate the and received day expansion still we IDHX TIBSOVO focused outstanding in have this filing on of year. refractory list and at XXX issues CHMP opinion receiving for AML end start, of the at we geographic indication one in a our
largest patients Phase number frontline frontline we X enrollment with focused on In are reach us studies global to to AML of the IDHX combination an which indication. will allow AML
azacitidine with combination in TIBSOVO standard in TIBSOVO Group the combination of study X the Phase IDHIFA AGILE study the HOVONXXX is is and of induction First second consolidation chemotherapy. and and with Cooperative
oncology continue shipments necessary. physicians overall to including tolerated both patients to well therapy, home a refer been and have TIBSOVO studies patients as access able As to
in to activations site the activity the AGILE enrollment at a across in as trial now of complete enrollment China enrollment pandemic. of delays complete XXXX However, end due interruptions to result interruptions has the projected startup is sites we have this site slowed some The to occurred which globe. and expected in originally and QX year, by
has and on the enrollment as provide in Chinese more countries away expect have for sites impacted completion Europe some sites the at HOVONXXX sites in to been heavily are work trial crisis able move countries open majority The to study return pre-pandemic environments. of weeks, recent to from In and timing we precise enrollment clinical slowed. and
and We be along we are accrual make a process certainly able to in early way. is time study, some up still since it the relatively the long may
have expected rates. activated We accrual agreed will an update and we provide all sites once completion are on enrollment on
Beyond the with a AML, U.S. Phase pursue regulatory generating to the early this reopening goal for study and up we study, experienced TIBSOVO is have of now starting the in on we delays are the Myelodysplastic process enrollment X expected the of completion filing. data Syndrome sites potential XXXX. activities in Since necessary recently reopened
inhibitor being in XXXX. advanced year of Phase go go, the turn of lymphoma. escalation beginning no the on I'll At further end our to AG-XXX dose make DHODH AG-XXX in planned by Finally a a we as currently evaluated study the of development to X decision
in months, this for the result, of all plant patients to decision the total exercise As we the that stop highlighted, to in for At to made a a of look very program. in-house and development. XX we course prioritization a partner XX a limited the time, have invest enrollment study, Jackie
with risk to move evaluating inhibitor solid cholangiocarcinoma in AG-XXX, pancreatic MATXA are pivotal the low grade clarity readout now cancers. a or recorded in cholangiocarcinoma I'll reduced tumors in study in the we XX%. positive of in showing combination studies inhibitors death progression TIBSOVO Phase and advancing of disease of with the that and by IDH year we treatment taxanes glioma where IDH-X treated and X previously lung Last TIBSOVO
study survival challenges had outbreak [indiscernible] In resources, it collecting we have matured of potential we this Based process. on mid the data filing. the the anticipate XXXX has NDA overall from data site sites expect a supplemental support daily cleaning to on COVID-XX the to and current state impact trial from the and in executing
sometime sNDA this, Given not XXXX. and the occur end toward the of the is of middle submission XXXX likely to
The X a is vorasidenib, in glioma inhibitor, December. low our brain-penetrant our trial that INDIGO IDH of study Phase initiated grade
startup pandemic. of and result the some as enrollment experiencing currently are a delays We
the study way. Given to long a will the this able early likely it make along be stage timeline is we some up and time of
enrollment and study accrual rates. glioma the completion We grade data meantime, ASCO a low expected X will activated of to view look we non-enhancing in on better at sites forward the provide from Phase update an updated have in In all have May. vorasidenib once late we sharing on been
X still slowed We Lastly, COVID-XX to the have been no dose expect be go, the arms shipped but AG-XXX later sites in ongoing, combination decision this due as is able to enrollment on at some make Phase a to XXXX. escalation resources program has go no pandemic. than
beyond trial far crisis is make it clinical implications of best and clinical duty of team over medical operations To our colleagues The are our from and call patients. and and to the going partners these of informed, leadership well that as operations response interest as their in we're all safety like regulatory close, our this with to hard the for I'd months. and of decisions able work last few thank above stay technical support
With Darrin to to performance. quarter discuss first our that, I'll turn over it commercial
